Blueprint to pull Gavreto in certain markets, shelve EGFR programs as it focuses on Ayvakit launchnews2024-01-09T14:07:23+00:00January 9th, 2024|Endpoints News|
Jennifer Doudna, Fyodor Urnov want to streamline gene editing studies with Danaher’s helpnews2024-01-09T12:30:40+00:00January 9th, 2024|Endpoints News|
Athersys files for Chapter 11 bankruptcy, sells everything to partner Healiosnews2024-01-09T12:04:40+00:00January 9th, 2024|Endpoints News|
Astellas hit with CRL for Claudin 18.2 drug due to third-party manufacturing concernsnews2024-01-09T11:44:39+00:00January 9th, 2024|Endpoints News|
#JPM24: RTW, Bayer back Cytokinetics-allied Ji Xing Pharmaceuticals with $162Mnews2024-01-09T10:30:02+00:00January 9th, 2024|Endpoints News|
#JPM24: GSK to buy asthma biotech Aiolos Bio for up to $1.4B three months after startup emergednews2024-01-09T07:56:32+00:00January 9th, 2024|Endpoints News|
#JPM24: Amazon launches program to connect customers with digital health benefitsnews2024-01-09T07:38:59+00:00January 9th, 2024|Endpoints News|
#JPM24: Ultragenyx nears $50M Series A for its Alzheimer’s gene therapy spinoutnews2024-01-09T07:29:52+00:00January 9th, 2024|Endpoints News|
#JPM24 quick hits: A ‘great year for M&A’; an optimistic Sarepta; Pfizer’s CEO + morenews2024-01-09T06:37:35+00:00January 9th, 2024|Endpoints News|
#JPM24: Pfizer CEO says it’s back to basics after painful 2023 for investorsnews2024-01-08T23:01:52+00:00January 8th, 2024|Endpoints News|
